Biotech innovation is rapidly transforming the boundaries of modern wellness, and CEAS Collective stands at the forefront of this shift. By integrating advanced product development with a direct-to-patient delivery model, CEAS Collective bridges the gap between next-generation health solutions and consumer-centric care. Their approach sets a new benchmark for accessible, holistic wellness, offering patients seamless access to science-driven products…
The Future Biotech Expo is a premier international red biotechnology exhibition and conference dedicated to accelerating breakthroughs across the industry vertical that are shaping the future of healthcare and medicine across the globe and beyond.
Future Biotech Expo features a world-class exhibition, thought-provoking conferences, startup showcases, structured B2B matchmaking, and a dedicated Hosted Buyer Program…
Shots:
The Fourth quarter of 2024 highlights major acquisitions in the pharma and biotech industry along with clinical trial results and approvals. The highlight of the quarter was Roche's acquisition of Poseida Therapeutics for ~$1.5B
This quarter also showcased multiple clinical trial results including Pfizer's P-III Study Data of Talzenna + Xtandi to treat mCRPC …
The fourth quarter of 2020 contains multiple initiations of clinical trials, big approvals, and numerous deals. COVID-19 related news remains at the peak in this quarter
Multiple companies received regulatory bodies EUA for their vaccines and treatments for COVID-19. Initiating with, Regeneron sought the US FDA's EUA for REGN-COV2 Ab combination while Health Canada accelerated…

